Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Fly Intel: Top five analyst downgrades » 09:55
09/10/21
09/10
09:55
09/10/21
09:55
CFX

Colfax

$46.92 /

-0.035 (-0.07%)

, SUMO

Sumo Logic

$17.97 /

-2.18 (-10.82%)

, FCX

Freeport McMoRan

$36.09 /

+1.28 (+3.68%)

, HGEN

Humanigen

$7.15 /

-0.81 (-10.18%)

, CI

Cigna

$206.20 /

-7.765 (-3.63%)

Catch up on today's…

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Colfax (CFX) downgraded to Neutral from Buy at Goldman Sachs with analyst Joe Ritchie saying his estimates are no longer differentiated versus consensus and that he sees less potential for the stock to re-rate at this point in the cycle. 2. Sumo Logic (SUMO) downgraded to Neutral from Buy at BTIG with analyst Gray Powell saying the company's Q2 results were "solid" with 29% headline billings growth topping his 25% estimate, and the management increased its total revenue guidance by about 1%, but some underlying trends were concerning as revenue upside in the full-year outlook was driven entirely by improved trends at Sumo's largest customer. 3. Freeport McMoRan (FCX) downgraded to Underperform from Neutral at Credit Suisse with analyst Curt Woodworth saying copper prices are more a reflection of future inflation expectations than a real-time gauge of the health of the global economy, Woodworth tells investors in a research note and adding he is concerned that the market is "overly bullish" on the medium term demand uptake from electric vehicles and renewables. 4. Humanigen (HGEN) downgraded to Hold from Buy at Jefferies with analyst Kelly Shi noting that the FDA invited Humanigen to submit additional data after denying its EUA request. 5. Cigna (CI) downgraded to Underperform from Buy at BofA with analyst Kevin Fischbeck saying while the company has now integrated Express Scripts successfully, de-levered, and sold off underperforming units, the growth outlook from here is "less clear" and he sees lower visibility in its earnings trajectory over the next couple of years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
SUMO Sumo Logic
$17.97 /

-2.18 (-10.82%)

HGEN Humanigen
$7.15 /

-0.81 (-10.18%)

FCX Freeport McMoRan
$36.09 /

+1.28 (+3.68%)

CI Cigna
$206.20 /

-7.765 (-3.63%)

CFX Colfax
$46.92 /

-0.035 (-0.07%)

09/10/21 Goldman Sachs
Colfax downgraded to Neutral from Buy at Goldman Sachs
08/16/21 Argus
Colfax price target raised to $56 from $50 at Argus
04/06/21
Fly Intel: Top five analyst downgrades
04/06/21 Barclays
Colfax downgraded to Underweight from Equal Weight at Barclays
SUMO Sumo Logic
$17.97 /

-2.18 (-10.82%)

09/10/21 BTIG
Sumo Logic downgraded to Neutral from Buy at BTIG
09/10/21 Piper Sandler
Sumo Logic downgraded to Neutral from Overweight at Piper Sandler
06/04/21 RBC Capital
Sumo Logic price target lowered to $25 from $30 at RBC Capital
06/04/21 BTIG
Sumo Logic price target lowered to $27 from $35 at BTIG
FCX Freeport McMoRan
$36.09 /

+1.28 (+3.68%)

09/10/21 Credit Suisse
Credit Suisse downgrades Freeport McMoRan to sell on copper price risk
09/10/21 Credit Suisse
Freeport McMoRan downgraded to Underperform from Neutral at Credit Suisse
07/23/21 Deutsche Bank
Freeport McMoRan price target lowered to $47 from $50 at Deutsche Bank
07/08/21
Fly Intel: Top five analyst downgrades
HGEN Humanigen
$7.15 /

-0.81 (-10.18%)

09/10/21 Jefferies
Humanigen downgraded to Hold from Buy at Jefferies
09/09/21 Credit Suisse
Credit Suisse cuts Humanigen to Neutral after FDA denies lenzilumab EUA
09/09/21 Credit Suisse
Humanigen downgraded to Neutral from Outperform at Credit Suisse
09/09/21 Roth Capital
Roth cuts Humanigen target but sees potential EUA from collective data
CI Cigna
$206.20 /

-7.765 (-3.63%)

09/10/21 BofA
Cigna downgraded to Underperform from Buy at BofA
09/09/21 Cowen
Cigna initiated with a Market Perform at Cowen
09/08/21 Mizuho
Selloff in managed care sector overdone, says Mizuho
08/20/21 Benchmark
Ontrak price target lowered to $16 from $35 at Benchmark
SUMO Sumo Logic
$17.97 /

-2.18 (-10.82%)

HGEN Humanigen
$7.15 /

-0.81 (-10.18%)

FCX Freeport McMoRan
$36.09 /

+1.28 (+3.68%)

CI Cigna
$206.20 /

-7.765 (-3.63%)

CFX Colfax
$46.92 /

-0.035 (-0.07%)

  • 29
    Jul
  • 31
    Mar
  • 17
    Mar
  • 18
    Sep
  • 17
    Sep
FCX Freeport McMoRan
$36.09 /

+1.28 (+3.68%)

CI Cigna
$206.20 /

-7.765 (-3.63%)

SUMO Sumo Logic
$17.97 /

-2.18 (-10.82%)

HGEN Humanigen
$7.15 /

-0.81 (-10.18%)

FCX Freeport McMoRan
$36.09 /

+1.28 (+3.68%)

CI Cigna
$206.20 /

-7.765 (-3.63%)

SUMO Sumo Logic
$17.97 /

-2.18 (-10.82%)

HGEN Humanigen
$7.15 /

-0.81 (-10.18%)

FCX Freeport McMoRan
$36.09 /

+1.28 (+3.68%)

Downgrade
Colfax downgraded to Neutral from Buy at Goldman Sachs » 04:54
09/10/21
09/10
04:54
09/10/21
04:54
CFX

Colfax

$46.94 /

-0.27 (-0.57%)

Goldman Sachs analyst Joe…

Goldman Sachs analyst Joe Ritchie downgraded Colfax to Neutral from Buy with a price target of $51, down from $53. The analyst says his estimates are no longer differentiated versus consensus and that he sees less potential for the stock to re-rate at this point in the cycle. The stock has outperformed year-to-date and it's hard to argue for multiple re-rating here given the early cycle nature of both segments and the free cash flow characteristics, Ritchie tells investors in a research note.

ShowHide Related Items >><<
CFX Colfax
$46.94 /

-0.27 (-0.57%)

08/16/21 Argus
Colfax price target raised to $56 from $50 at Argus
04/06/21
Fly Intel: Top five analyst downgrades
04/06/21 Barclays
Colfax downgraded to Underweight from Equal Weight at Barclays
03/30/21 Baird
Colfax upside remains following equity transaction, says Baird
CFX Colfax
$46.94 /

-0.27 (-0.57%)

  • 29
    Jul
  • 17
    Mar
Over a month ago
Recommendations
Colfax price target raised to $56 from $50 at Argus » 08:17
08/16/21
08/16
08:17
08/16/21
08:17
CFX

Colfax

$49.66 /

-0.28 (-0.56%)

Argus analyst John Eade…

Argus analyst John Eade raised the firm's price target on Colfax to $56 from $50 and keeps a Buy rating on the shares. The analyst sees the company as a "well-managed" mid-cap company with a new focus on med-tech. Colfax's 2020 earnings were weak due to the impact of the coronavirus, but results have been improving quarter to quarter, and the recent healthcare company acquisitions should build momentum, Eade tells investors in a research note.

ShowHide Related Items >><<
CFX Colfax
$49.66 /

-0.28 (-0.56%)

CFX Colfax
$49.66 /

-0.28 (-0.56%)

04/06/21
Fly Intel: Top five analyst downgrades
04/06/21 Barclays
Colfax downgraded to Underweight from Equal Weight at Barclays
03/30/21 Baird
Colfax upside remains following equity transaction, says Baird
03/16/21 Citi
Colfax equity offering not overly surprising, says Citi
CFX Colfax
$49.66 /

-0.28 (-0.56%)

  • 29
    Jul
  • 17
    Mar
Syndicate
Colfax 6.54M share Spot Secondary priced at $43.90 » 06:46
07/29/21
07/29
06:46
07/29/21
06:46
CFX

Colfax

$45.28 /

+0.32 (+0.71%)

The deal range was…

The deal range was $43.88-$44.88. Morgan Stanley acted as sole book running manager for the offering.

ShowHide Related Items >><<
CFX Colfax
$45.28 /

+0.32 (+0.71%)

CFX Colfax
$45.28 /

+0.32 (+0.71%)

04/06/21
Fly Intel: Top five analyst downgrades
04/06/21 Barclays
Colfax downgraded to Underweight from Equal Weight at Barclays
03/30/21 Baird
Colfax upside remains following equity transaction, says Baird
03/16/21 Citi
Colfax equity offering not overly surprising, says Citi
CFX Colfax
$45.28 /

+0.32 (+0.71%)

  • 29
    Jul
  • 17
    Mar
Syndicate
Colfax announces offering of 6.54M shares of common stock for holders » 16:38
07/28/21
07/28
16:38
07/28/21
16:38
CFX

Colfax

$45.28 /

+0.32 (+0.71%)

Colfax Corporation…

Colfax Corporation announced that certain of its stockholders have commenced an underwritten secondary offering of 6.54M shares of the company's common stock. Morgan Stanley is acting as sole book-running manager for the offering.

ShowHide Related Items >><<
CFX Colfax
$45.28 /

+0.32 (+0.71%)

CFX Colfax
$45.28 /

+0.32 (+0.71%)

04/06/21
Fly Intel: Top five analyst downgrades
04/06/21 Barclays
Colfax downgraded to Underweight from Equal Weight at Barclays
03/30/21 Baird
Colfax upside remains following equity transaction, says Baird
03/16/21 Citi
Colfax equity offering not overly surprising, says Citi
CFX Colfax
$45.28 /

+0.32 (+0.71%)

  • 17
    Mar
Earnings
Colfax raises FY21 EPS view to $2.10-$2.20, consensus $2.15  16:38
07/28/21
07/28
16:38
07/28/21
16:38
CFX

Colfax

$45.28 /

+0.32 (+0.71%)

 
ShowHide Related Items >><<
CFX Colfax
$45.28 /

+0.32 (+0.71%)

CFX Colfax
$45.28 /

+0.32 (+0.71%)

04/06/21
Fly Intel: Top five analyst downgrades
04/06/21 Barclays
Colfax downgraded to Underweight from Equal Weight at Barclays
03/30/21 Baird
Colfax upside remains following equity transaction, says Baird
03/16/21 Citi
Colfax equity offering not overly surprising, says Citi
CFX Colfax
$45.28 /

+0.32 (+0.71%)

  • 17
    Mar
Earnings
Colfax sees Q3 EPS 50c-55c , consensus 56c  16:36
07/28/21
07/28
16:36
07/28/21
16:36
CFX

Colfax

$45.28 /

+0.32 (+0.71%)

 
ShowHide Related Items >><<
CFX Colfax
$45.28 /

+0.32 (+0.71%)

CFX Colfax
$45.28 /

+0.32 (+0.71%)

04/06/21
Fly Intel: Top five analyst downgrades
04/06/21 Barclays
Colfax downgraded to Underweight from Equal Weight at Barclays
03/30/21 Baird
Colfax upside remains following equity transaction, says Baird
03/16/21 Citi
Colfax equity offering not overly surprising, says Citi
CFX Colfax
$45.28 /

+0.32 (+0.71%)

  • 17
    Mar
Earnings
Colfax reports Q2 EPS 56c, consensus 53c » 16:35
07/28/21
07/28
16:35
07/28/21
16:35
CFX

Colfax

$45.28 /

+0.32 (+0.71%)

Reports Q2 revenue…

Reports Q2 revenue $985.9M, consensus $917.93M.

ShowHide Related Items >><<
CFX Colfax
$45.28 /

+0.32 (+0.71%)

CFX Colfax
$45.28 /

+0.32 (+0.71%)

04/06/21
Fly Intel: Top five analyst downgrades
04/06/21 Barclays
Colfax downgraded to Underweight from Equal Weight at Barclays
03/30/21 Baird
Colfax upside remains following equity transaction, says Baird
03/16/21 Citi
Colfax equity offering not overly surprising, says Citi
CFX Colfax
$45.28 /

+0.32 (+0.71%)

  • 17
    Mar
Over a quarter ago
Earnings
Colfax raises FY21 adjusted EPS view to $2.05-$2.15 from $2.00-$2.15 » 06:09
04/29/21
04/29
06:09
04/29/21
06:09
CFX

Colfax

$45.69 /

-0.02 (-0.04%)

FY21 consensus $2.12.…

FY21 consensus $2.12. Cites the strength of first quarter results.

ShowHide Related Items >><<
CFX Colfax
$45.69 /

-0.02 (-0.04%)

CFX Colfax
$45.69 /

-0.02 (-0.04%)

04/06/21
Fly Intel: Top five analyst downgrades
04/06/21 Barclays
Colfax downgraded to Underweight from Equal Weight at Barclays
03/30/21 Baird
Colfax upside remains following equity transaction, says Baird
03/16/21 Citi
Colfax equity offering not overly surprising, says Citi
CFX Colfax
$45.69 /

-0.02 (-0.04%)

  • 17
    Mar
Earnings
Colfax sees Q2 adjusted EPS 48c-53c, consensus 53c  06:08
04/29/21
04/29
06:08
04/29/21
06:08
CFX

Colfax

$45.69 /

-0.02 (-0.04%)

 
ShowHide Related Items >><<
CFX Colfax
$45.69 /

-0.02 (-0.04%)

CFX Colfax
$45.69 /

-0.02 (-0.04%)

04/06/21
Fly Intel: Top five analyst downgrades
04/06/21 Barclays
Colfax downgraded to Underweight from Equal Weight at Barclays
03/30/21 Baird
Colfax upside remains following equity transaction, says Baird
03/16/21 Citi
Colfax equity offering not overly surprising, says Citi
CFX Colfax
$45.69 /

-0.02 (-0.04%)

  • 17
    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.